#BEGIN_DRUGCARD DB03787

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
Not Available

# Chemical_Formula:
C11H16N3O7P

# Chemical_IUPAC_Name:
{[5-hydroxy-6-methyl-4-({[(4R)-3-oxo-1,2-oxazolidin-4-yl]amino}methyl)pyridin-3-yl]methoxy}phosphonic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
L-Pyridoxyl-N,O-Cycloserylamide-5-Monophosphate

# HET_ID:
LCS

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C11H16N3O7P/c1-6-10(15)8(3-13-9-5-20-14-11(9)16)7(2-12-6)4-21-22(17,18)19/h2,9,13,15H,3-5H2,1H3,(H,14,16)(H2,17,18,19)/t9-/m1/s1

# InChI_Key:
InChIKey=NNRZSZJOQKAGTO-SECBINFHSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
3787

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
333.2344

# Molecular_Weight_Mono:
333.072586393

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1D7U

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
-1.4

# Predicted_LogS:
-2.2

# Predicted_Water_Solubility:
2.21e+00 g/l

# Primary_Accession_No:
DB03787

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
445005

# PubChem_Substance_ID:
46504796

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT02011

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CC1=NC=C(COP(O)(O)=O)C(CN[C@@H]2CONC2=O)=C1O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:22:37 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Not Available

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
J05282

# Drug_Target_1_GenBank_ID_Protein:
559963

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
dgdA

# Drug_Target_1_Gene_Sequence:
>1302 bp
ATGTCCCTGAACGACGATGCAACCTTCTGGCGCAACGCCAGGCAGCACCTGGTCCGCTAC
GGCGGCACGTTCGAGCCGATGATCATCGAGCGCGCGAAGGGCAGCTTCGTCTATGACGCC
GACGGCCGCGCGATCCTCGATTTCACGTCGGGGCAGATGAGCGCGGTGCTCGGCCACTGC
CATCCGGAGATCGTCTCCGTCATCGGCGAATACGCGGGCAAGCTCGATCACCTGTTCAGC
GGAATGCTGTCGCGGCCCGTCGTCGACCTCGCGACGCGCCTCGCCAACATCACGCCGCCC
GGGCTCGACCGCGCGCTGCTGCTCAGCACCGGCGCGGAATCGAACGAAGCGGCAATCCGG
ATGGCGAAGCTCGTCACCGGCAAGTACGAGATCGTCGGCTTCGCGCAGTCGTGGCACGGG
ATGACGGGCGCGGCCGCATCGGCCACGTACAGCGCGGGCCGCAAGGGTGTCGGCCCGGCC
GCCGTCGGCTCGTTCGCGATTCCGGCGCCATTCACGTACCGGCCGCGCTTCGAGCGCAAC
GGCGCGTACGACTATCTCGCCGAACTCGACTACGCGTTCGACCTGATCGACCGCCAGTCG
AGCGGCAACCTCGCGGCATTCATCGCGGAGCCGATCCTCAGTTCGGGCGGGATCATCGAA
CTGCCGGACGGCTACATGGCGGCGCTCAAGCGCAAGTGCGAGGCGCGCGGGATGCTGCTG
ATCCTCGACGAGGCGCAGACGGGCGTCGGACGCACCGGCACGATGTTCGCGTGCCAGCGC
GACGGCGTGACGCCCGACATCCTGACGCTGTCGAAAACGCTCGGCGCCGGGCTGCCGCTC
GCGGCCATCGTGACGTCCGCGGCGATCGAGGAACGCGCGCACGAACTCGGCTACCTGTTC
TATACGACGCACGTGTCCGATCCGCTGCCCGCGGCGGTCGGCCTGCGCGTGCTCGACGTG
GTGCAGCGCGACGGGCTCGTCGCACGCGCGAACGTGATGGGCGACCGGCTCAGGCGCGGC
CTGCTCGACCTGATGGAGCGGTTCGACTGCATCGGCGACGTGCGCGGGCGCGGGCTGCTG
CTCGGCGTCGAGATCGTCAAGGATCGACGCACGAAAGAGCCGGCGGACGGCCTCGGCGCG
AAGATCACGCGCGAGTGCATGAACCTCGGGCTCAGCATGAACATCGTGCAGTTGCCCGGC
ATGGGCGGCGTGTTCCGGATCGCGCCGCCGCTGACGGTCAGCGAGGACGAGATCGATCTC
GGCTTGTCGCTGCTCGGTCAGGCGATCGAACGCGCGCTGTAA

# Drug_Target_1_General_Function:
Amino acid transport and metabolism

# Drug_Target_1_General_References:
10556038	Malashkevich VN, Strop P, Keller JW, Jansonius JN, Toney MD: Crystal structures of dialkylglycine decarboxylase inhibitor complexes. J Mol Biol. 1999 Nov 19;294(1):193-200.
2180928	Keller JW, Baurick KB, Rutt GC, O'Malley MV, Sonafrank NL, Reynolds RA, Ebbesson LO, Vajdos FF: Pseudomonas cepacia 2,2-dialkylglycine decarboxylase. Sequence and expression in Escherichia coli of structural and repressor genes. J Biol Chem. 1990 Apr 5;265(10):5531-9.
7799433	Toney MD, Hohenester E, Keller JW, Jansonius JN: Structural and mechanistic analysis of two refined crystal structures of the pyridoxal phosphate-dependent enzyme dialkylglycine decarboxylase. J Mol Biol. 1995 Jan 13;245(2):151-79.
7947767	Hohenester E, Keller JW, Jansonius JN: An alkali metal ion size-dependent switch in the active site structure of dialkylglycine decarboxylase. Biochemistry. 1994 Nov 22;33(46):13561-70.
8342040	Toney MD, Hohenester E, Cowan SW, Jansonius JN: Dialkylglycine decarboxylase structure: bifunctional active site and alkali metal sites. Science. 1993 Aug 6;261(5122):756-9.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
2740

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
46445

# Drug_Target_1_Name:
2,2-dialkylglycine decarboxylase

# Drug_Target_1_Number_of_Residues:
433

# Drug_Target_1_PDB_ID:
1D7S

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00202	Aminotran_3

# Drug_Target_1_Protein_Sequence:
>2,2-dialkylglycine decarboxylase
MSLNDDATFWRNARQHLVRYGGTFEPMIIERAKGSFVYDADGRAILDFTSGQMSAVLGHC
HPEIVSVIGEYAGKLDHLFSGMLSRPVVDLATRLANITPPGLDRALLLSTGAESNEAAIR
MAKLVTGKYEIVGFAQSWHGMTGAAASATYSAGRKGVGPAAVGSFAIPAPFTYRPRFERN
GAYDYLAELDYAFDLIDRQSSGNLAAFIAEPILSSGGIIELPDGYMAALKRKCEARGMLL
ILDEAQTGVGRTGTMFACQRDGVTPDILTLSKTLGAGLPLAAIVTSAAIEERAHELGYLF
YTTHVSDPLPAAVGLRVLDVVQRDGLVARANVMGDRLRRGLLDLMERFDCIGDVRGRGLL
LGVEIVKDRRTKEPADGLGAKITRECMNLGLSMNIVQLPGMGGVFRIAPPLTVSEDEIDL
GLSLLGQAIERAL

# Drug_Target_1_Reaction:
2,2-dialkylglycine + pyruvate = dialkyl ketone + CO2 + L-alanine

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
The dialkylglycine decarboxylase is of interest because it normally catalyzes both decarboxylation and amino transfer. It may be more properly described as a decarboxylating aminotransferase rather than an aminotransferring decarboxylase

# Drug_Target_1_SwissProt_ID:
P16932

# Drug_Target_1_SwissProt_Name:
DGDA_BURCE

# Drug_Target_1_Synonyms:
DGD
EC 4.1.1.64

# Drug_Target_1_Theoretical_pI:
5.95

# Drug_Target_1_Transmembrane_Regions:
None

#END_DRUGCARD DB03787
